Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet.

Latest News

    No posts were found.

Share this


6B Liberty, Suite 230, Aliso Viejo, CA. 92656

Liquid BiosciencesPress Release Blueprint Bio and Emerald Logic MERGE to Create Healthcare Innovation Company liquid biosciences, inc.

Blueprint Bio and Emerald Logic MERGE to Create Healthcare Innovation Company liquid biosciences, inc.

Blueprint Bio and Emerald Logic MERGE to Create Healthcare Innovation Company liquid biosciences, inc.

New Entity Will Advance Precision Medicine through Actionable Insights –

Aliso Viejo, CA – August 15, 2017 – BluePrint Bio and Emerald Logic, providers of innovative diagnostics and analytics used to inform precision medicine, today announced the merger of the two companies to create one private entity, Liquid BioSciences, Inc. The new company will combine a highly scientific biomarker research model with sophisticated predictive health algorithms into one solution with the potential to transform clinical decisions and patient outcomes. Dennis Kogod has been appointed chairman and chief executive officer of Liquid BioSciences, joining the organization from DaVita HealthCare Partners International, where he served as chief executive officer.


“Precision medicine has the potential to change the current one-size-fits-all approach in healthcare and personalize treatments to produce game-changing improvements in patient outcomes,” said Dennis Kogod, Liquid Biosciences’ chairman and chief executive officer. “The merger of Blueprint Bio and Emerald Logic brings together a seasoned leadership team with extensive expertise in healthcare analytics and biomarker identification, as well as a shared mission to advance the rapidly evolving science of precision medicine.”


Liquid BioSciences combines the use of a comprehensive multi-omics platform with a novel bio-inspired signal processing analytic technology to provide a powerful solution to extremely complex data sets. The company’s platform has been tested on over 100 validation projects and Liquid BioSciences’ intellectual property comprises 115+ trade secrets and patents in the areas of biomarker discoveries, core bio-analytics technology and market-responsive solutions.


“Liquid Biosciences has the potential to transform the way we make clinical decisions by allowing us to perform a comprehensive evaluation of a set of individual patient information,” said Barry Straube, M.D., Former Chief Medical Officer for the Centers for Medicare and Medicaid Services (CMS). “As a result, we will better predict individual patient responses to available therapies and enable early personalized interventions to improve clinical outcomes while avoiding unnecessary costs.”


Healthcare providers, managed care organizations and clinical investigators can utilize Liquid BioSciences’ technology to predict clinical outcomes for clinical trial screening and recruitment, create individualized interventions for patients and further their understanding of the mechanisms of disease and disease progression. This approach has the potential to allow for more targeted pathways to drive better clinical decisions and patient outcomes, despite how complex treatment decisions can be.


“The human body is a highly-complex and non-linear system, which makes it challenging to accurately model and predict patient outcomes even with state-of-the art machine learning methods. Liquid’s platform, however, can concurrently analyze many thousands to millions of variables per patient and produce highly-accurate, human-readable models,” said Dr. Michael B. Yaffe, Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology.


In addition to the appointment of Mr. Kogod, Liquid BioSciences has engaged critical staff members from the two original organizations, including Patrick Lilley, CEO and founder of Emerald Logic, and Matthew Nunez, CEO and founder of BluePrint Bio. The management team of Liquid BioSciences will include:

  • Frank Prendergast, MD, PhD, Board Member: Dr. Prendergast was previously the Director for the Mayo Clinic Center for Individualized Medicine at the Mayo Clinic and the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology at the Mayo Medical School. Dr. Prendergast holds an M.A. in Physiology from Oxford University, a B.A. in Physiology from Oxford University and a Medical Degree from the University of the West Indies.
  • Barry Straube, MD Board Member: Dr. Straube served as the Chief Medical Officer for the Centers for Medicare & Medicaid Services (CMS) and Director of the CMS Office of Clinical Standards & Quality (OCSQ) until February 2011. Dr. Straube holds an A.B. degree from Princeton University and received his M.D. degree from the University of Michigan Medical School.
  • Kevin Manion, Board Member: Manion is the Chief Financial Officer for Green Dot Operating Company. Kevin formerly served as the Chief Financial Officer for Young’s Market Company a $2.9 billion, 125 year, family owned distributor of wine and liquor servicing the happiness needs of the Western United States.
  • Dennis Kogod, Chairman and CEO: Kogod has over 30 years of experience in senior management roles at companies specializing in healthcare services and specialized medical solutions. Most recently, he served as the CEO of DaVita HealthCare Partners International. He received his business degree from the University of Florida and has also completed several sales and management executive programs.
  • Patrick Lilley, Co-Founder & Chief Data Scientist: Lilley has spent the last 25 years driving growth and innovation in biotech, software, high-performance computing and mobile wireless, most recently as CEO and founder of Emerald Logic. He holds a B.A. in Economics and a master’s degree in Business Administration specializing in quantitative finance, both from University of California, Irvine.
  • Matthew Nunez, Co-Founder: Nunez brings 15 years of operational experience having most recently served as founder and CEO of BluePrint Bio as well as co-founder and CEO of BluePen Biomarkers, a joint venture between BluePrint Bio, Emerald Logic and the University of Pennsylvania.
  • Pooja Goel, Chief Commercial Officer: Goel is a seasoned healthcare executive with over two decades of experience in the healthcare services delivery sector. She was recently at Landmark Health. Pooja holds a bachelor’s degree in Microbiology and Molecular genetics from the University of California, Los Angeles and a master’s degree in Health Administration from the Loma Linda University School of Public Health.


Visit the Liquid BioSciences’ website for additional information at


About Liquid BioSciences, Inc.

Liquid BioSciences is a healthcare innovation company that enables the precise delivery of clinical care by removing guesswork, variable diagnoses and treatment strategies based on one-size-fits-all medicine. Liquid BioSciences leverages data from direct and indirect sources to provide a more comprehensive view of an individual patient. The company uses its proprietary mathematics and multi-omics assay technology to predict clinical outcomes and enable early intervention to mitigate expensive downstream consequences. Additional information about Liquid BioSciences can be found here.


Media Contacts:

Pooja Goel

Liquid BioSciences

Chief Commercial Officer



Edie DeVine

GCI Health on behalf of Liquid BioSciences